| Literature DB >> 19508922 |
Shalini Andersson1, Alan Armstrong, Annika Björe, Sue Bowker, Steve Chapman, Rob Davies, Craig Donald, Bryan Egner, Thomas Elebring, Sara Holmqvist, Tord Inghardt, Petra Johannesson, Magnus Johansson, Craig Johnstone, Paul Kemmitt, Jan Kihlberg, Pernilla Korsgren, Malin Lemurell, Jane Moore, Jonas A Pettersson, Helen Pointon, Fritiof Pontén, Paul Schofield, Nidhal Selmi, Paul Whittamore.
Abstract
The pharmaceutical industry, particularly the small molecule domain, faces unprecedented challenges of escalating costs, high attrition as well as increasing competitive pressure from other companies and from new treatment modes such as biological products. In other industries, process improvement approaches, such as Lean Sigma, have delivered benefits in speed, quality and cost of delivery. Examining the medicinal chemistry contributions to the iterative improvement process of design-make-test-analyse from a Lean Sigma perspective revealed that major improvements could be made. Thus, the cycle times of synthesis, as well as compound analysis and purification, were reduced dramatically. Improvements focused on team, rather than individual, performance. These new ways of working have consequences for staff engagement, goals, rewards and motivation, which are also discussed.Mesh:
Substances:
Year: 2009 PMID: 19508922 DOI: 10.1016/j.drudis.2009.03.005
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851